NewsBenzingaRBC Capital mantiene il rating Outperform su Corbus Pharmaceuticals, abbassa il target di prezzo a 33 $ RBC Capital mantiene il rating Outperform su Corbus Pharmaceuticals, abbassa il target di prezzo a 33 $ Benzinga 2026.11.11 15:18 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3